polycythemia vera

Pipobroman (Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. Pipobroman has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). Pipobroman allows, within 3 months, to attain a response in more than 90% of patients, without clinically relevant toxicities. The 10-years risk of thrombosis of patients treated with Pipobroman is about 15%, The anti-proliferative activity of Pipobroman on bone marrow megakaryocytes seems of particular value in lowering the occurrence of post-PV and post-ET MMM, whose risk is the lowest registered with available treatments. The 10-year risk of acute leukemia with Pipobroman is 5% in PVand 3% in ET, which is only slightly higher than that expected as a natural evolution of the disease. In conclusion, the use of Pipobroman is a definite alternative to hydroxyurea in patients with PV and ET at high risk of thrombosis.

JAK2-IN-13 is a potent and orally active JAK2 inhibitor with an IC50 of 54.7 nM. It downregulates the expression of p-STAT3 and p-STAT5 and exhibits good bioavailability. JAK2-IN-13 effectively suppresses recombinant human erythropoietin-induced extramedullary erythropoiesis as well as polycythemia vera. It is used in the study of myeloproliferative neoplasms.

Sapablursen is an antisense oligonucleotide that reduces the production of TMPRSS6, thereby increasing serum hepcidin levels. Serum hepcidin is a crucial regulator of iron homeostasis. Sapablursen can be used in studies of hematological disorders, such as polycythemia vera.

Sapablursen sodium is an antisense oligonucleotide that reduces the production of TMPRSS6, leading to increased expression of serum hepcidin, which is a key regulator of iron homeostasis. Sapablursen may be used in research on blood disorders such as polycythemia vera.

Ranimustine (MCNU) can be used for polycythemia vera and chronic myelogenous leukemia research, which is a nitrosourea alkylating agent [1] [3] [4].

ZT55, an orally active, highly-selective JAK2 inhibitor with an IC50 of 0.031 μM, inhibits proliferation of JAK2 V617F-expressing HEL cell lines, induces apoptosis and cycle arrest, and effectively inhibits HEL xenograft tumor growth in mice models. Suitable for studies on myeloproliferative neoplasms, polycythemia vera, and primary thrombocythemia, ZT55 offers promising applications.

Cepeginterferon alfa-2b, a pegylated interferon, features a polyethylene glycol (PEG) base with a molecular weight of 20 kDa. This compound is utilized in the research of numerous diseases, including hepatitis C virus (HCV), polycythemia vera (PV), and essential thrombocythemia (ET) [1] [2].

Rusfertide, a peptide mimetic of natural hepcidin, targets and degrades ferroportin, thereby reducing serum iron and transferrin saturation, which helps regulate red blood cell production. It ameliorates conditions such as polycythemia vera, β-thalassemia, and hereditary hemochromatosis [1] [2].